|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
82,110,000 |
Market
Cap: |
3.50(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$31.73 - $53.69 |
|
Level
I Sector: |
Consumer Discretionary |
Level
II Sector: |
Leisure |
Level
III Sector: |
Restaurants |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
|
NASDAQ INDUSTRIAL |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
39,487 |
99,487 |
200,738 |
249,694 |
Total Sell Value |
$2,038,634 |
$4,824,734 |
$8,307,365 |
$10,494,293 |
Total People Sold |
7 |
8 |
9 |
12 |
Total Sell Transactions |
10 |
12 |
21 |
35 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kassberg Thomas Richard |
CBO & EVP |
|
2017-05-21 |
4 |
D |
$57.47 |
$23,793 |
D/D |
(414) |
76,604 |
|
- |
|
Sharp Shalini |
CFO & Executive Vice President |
|
2017-05-21 |
4 |
D |
$57.47 |
$23,793 |
D/D |
(414) |
55,846 |
|
- |
|
Huizenga Theodore Alan |
VP, Controller and PAO |
|
2017-05-21 |
4 |
D |
$57.47 |
$9,540 |
D/D |
(166) |
9,846 |
|
- |
|
Huang Dennis Karl |
EVP & Chief Tech Ops Officer |
|
2017-05-05 |
4 |
D |
$61.08 |
$43,061 |
D/D |
(705) |
11,221 |
|
- |
|
Huizenga Theodore Alan |
Controller and PAO |
|
2017-03-09 |
4 |
S |
$86.34 |
$215,845 |
D/D |
(2,500) |
9,709 |
|
- |
|
Sharp Shalini |
CFO & Executive Vice President |
|
2017-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
55,887 |
|
- |
|
Pinion John Richard |
See Remarks |
|
2017-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,700 |
12,495 |
|
- |
|
Parschauer Karah Herdman |
EVP and General Counsel |
|
2017-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
9,500 |
|
- |
|
Kassberg Thomas Richard |
CBO & EVP |
|
2017-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
76,790 |
|
- |
|
Kakkis Emil D |
President & CEO |
|
2017-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,000 |
432,647 |
|
- |
|
Huang Dennis Karl |
EVP & Chief Tech Ops Officer |
|
2017-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
11,795 |
|
- |
|
Sharp Shalini |
CFO & Executive Vice President |
|
2017-02-27 |
4 |
AS |
$80.14 |
$961,680 |
D/D |
(12,000) |
51,887 |
|
- |
|
Sharp Shalini |
CFO & Executive Vice President |
|
2017-02-27 |
4 |
OE |
$0.82 |
$9,780 |
D/D |
12,000 |
63,887 |
|
- |
|
Sharp Shalini |
CFO & Executive Vice President |
|
2016-12-23 |
4 |
OE |
$0.81 |
$5,265 |
D/D |
6,500 |
51,887 |
|
- |
|
Kakkis Emil D |
President & CEO |
|
2016-12-22 |
5 |
GD |
$0.00 |
$0 |
D/D |
27,500 |
419,647 |
|
- |
|
Aliski William |
|
|
2016-12-05 |
4 |
S |
$77.94 |
$469,160 |
D/D |
(6,000) |
59,985 |
|
- |
|
Aliski William |
|
|
2016-12-05 |
4 |
OE |
$21.00 |
$126,000 |
D/D |
6,000 |
65,985 |
|
- |
|
Huizenga Theodore Alan |
Controller and PAO |
|
2016-11-16 |
4 |
S |
$79.73 |
$159,460 |
D/D |
(2,000) |
11,134 |
|
- |
|
Huizenga Theodore Alan |
Controller and PAO |
|
2016-11-16 |
4 |
OE |
$21.00 |
$42,000 |
D/D |
2,000 |
13,134 |
|
- |
|
Kakkis Emil D |
President & CEO |
|
2016-11-15 |
4 |
AS |
$79.39 |
$1,625,753 |
D/D |
(20,000) |
447,147 |
|
- |
|
Sharp Shalini |
CFO & Executive Vice President |
|
2016-11-09 |
4 |
AS |
$70.06 |
$1,708,894 |
D/D |
(24,000) |
45,387 |
|
- |
|
Sharp Shalini |
CFO & Executive Vice President |
|
2016-11-09 |
4 |
OE |
$0.82 |
$19,560 |
D/D |
24,000 |
69,387 |
|
- |
|
Sharp Shalini |
CFO & Senior Vice President |
|
2016-10-19 |
4 |
AS |
$60.98 |
$736,820 |
D/D |
(12,000) |
45,387 |
|
- |
|
Sharp Shalini |
CFO & Senior Vice President |
|
2016-10-19 |
4 |
OE |
$0.82 |
$9,780 |
D/D |
12,000 |
57,387 |
|
- |
|
Kakkis Emil D |
President & CEO |
|
2016-10-14 |
4 |
AS |
$61.97 |
$1,260,360 |
D/D |
(20,000) |
467,147 |
|
- |
|
628 Records found
|
|
Page 20 of 26 |
|
|